Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Competing endogenous lncRNA 1 for miR-4707-5p and miR-4767 (CERNA1, also known as LOC100129973) is a long non-coding RNA (lncRNA) located on chromosome 15 in humans[1][5][10]. CERNA1 functions as a molecular sponge that binds miR-4707-5p and miR-4767, thereby negatively regulating their availability in vascular endothelial cells. By sequestering these microRNAs, CERNA1 prevents them from downregulating their respective targets, the apoptosis inhibitors API5 and BCL2L12, resulting in decreased apoptosis, particularly under stress conditions such as serum and growth factor deprivation. This regulatory axis suggests a potential, but as yet not clinically validated, link to disease processes such as cardiovascular disease through its regulation of endothelial cell survival[6][7][8]. CERNA1 is not a protein, receptor, enzyme, or canonical therapeutic target but is rather a functional RNA element involved in post-transcriptional gene regulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on competing endogenous lncRNA 1 for miR-4707-5p and miR-4767 (CERNA1).